Back

The urgency to treat LDL-c post MI: The role of PCSK9 mAbs in reaching goals.

27 August 2021 (13:10 - 13:20)
Organised by:
Congress Presentation Part of: Redefining intensive LDL-c management in high risk patients: The case for combination therapy Risk Factors and Prevention Open Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor Derek Connolly

City Hospital, Birmingham (United Kingdom of Great Britain & Northern Ireland)

3 More presentations in this session

Presentation thumbnail
LDL-c in the management of high CV risk: Changing the paradigm for prevention.
Professor K. Ray (London, GB)
Video
Presentation thumbnail
Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute.
Doctor C. Ballantyne (Houston, US)
Video
Presentation thumbnail
Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?
Professor J. Kastelein (Amsterdam, NL)
Video

Access the full session

Session thumbnail
Redefining intensive LDL-c management in high risk patients: The case for combination therapy
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

27 August 2021 13:10 CET
You may be interested in
thumbnail
ESC TV Today
Episode 26: Lp(a): the future starts now - Myocardial infarction in older age and frailty
thumbnail
Congress Session
The strength of scientific integration
thumbnail
Webinar
Risk assessment and lipid management in primary prevention